Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma

Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma

Background Programmed cell death receptor-1 (PD-1)-blocking antibodies are approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) cases ineligible for curative surgery or radiation. Notwithstanding, some patients experience inadequate responses or severe immune-rel...

Full description

Bibliographic Details
Main Authors: Jayesh Desai, Stephane Dalle, Jermaine Coward, Daniel Brungs, Andrew Mant, Margaret McGrath, Andrea Tazbirkova, Piotr Koralewski, Iwona Lugowska, Arunee Dechaphunkul, Virote Sriuranpong, James Oliviero, Philip Clingan, Rahul Ladwa, Eva Muñoz-Couselo, Henri Montaudié, Miguel-Ángel Berciano-Guerrero, Dean Laurence Harris, Susan Arnold, Samuel Fourie, Andriy Kurochkin, Daniel R Malan, Vinay Sharma, Hong Shue, Chaiyut Charoentum, Oleksandr Dudnichenko
Format: Article
Language:English
Published: BMJ Publishing Group 2023-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/10/e007637.full

Internet

https://jitc.bmj.com/content/11/10/e007637.full

Similar Items